WO2024094439A1 - A sub-assembly of a medicament delivery device - Google Patents
A sub-assembly of a medicament delivery device Download PDFInfo
- Publication number
- WO2024094439A1 WO2024094439A1 PCT/EP2023/079217 EP2023079217W WO2024094439A1 WO 2024094439 A1 WO2024094439 A1 WO 2024094439A1 EP 2023079217 W EP2023079217 W EP 2023079217W WO 2024094439 A1 WO2024094439 A1 WO 2024094439A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- adapter
- directed surface
- connector
- cap
- sub
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 80
- 230000001419 dependent effect Effects 0.000 claims description 3
- 229940079593 drug Drugs 0.000 description 13
- 206010039073 rheumatoid arthritis Diseases 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- -1 peptibodies Proteins 0.000 description 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 2
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000017578 LAG3 Human genes 0.000 description 2
- 208000000592 Nasal Polyps Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- GNGACRATGGDKBX-UHFFFAOYSA-N dihydroxyacetone phosphate Chemical compound OCC(=O)COP(O)(O)=O GNGACRATGGDKBX-UHFFFAOYSA-N 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 229960002087 pertuzumab Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- YXTKHLHCVFUPPT-YYFJYKOTSA-N (2s)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1r,2r)-1,2-dimethanidylcyclohexane;5-fluoro-1h-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 1
- ZKEZEXYKYHYIMQ-UHFFFAOYSA-N 3-cyclohexyl-1-(2-morpholin-4-yl-2-oxoethyl)-2-phenyl-1h-indole-6-carboxylic acid Chemical compound C=1C=CC=CC=1C=1N(CC(=O)N2CCOCC2)C2=CC(C(=O)O)=CC=C2C=1C1CCCCC1 ZKEZEXYKYHYIMQ-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 102000000506 Adenosine A2 Receptors Human genes 0.000 description 1
- 108010041368 Adenosine A2 Receptors Proteins 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 101710117995 B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 108050001413 B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 102100038078 CD276 antigen Human genes 0.000 description 1
- 101710185679 CD276 antigen Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- 239000012275 CTLA-4 inhibitor Substances 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 108010019673 Darbepoetin alfa Proteins 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 description 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 1
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000653548 Homo sapiens Trichoplein keratin filament-binding protein Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 1
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 1
- 102000003735 Mesothelin Human genes 0.000 description 1
- 108090000015 Mesothelin Proteins 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 239000012269 PD-1/PD-L1 inhibitor Substances 0.000 description 1
- 108091006006 PEGylated Proteins Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 102100029198 SLAM family member 7 Human genes 0.000 description 1
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 description 1
- 108010029157 Sialic Acid Binding Ig-like Lectin 2 Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 102100030645 Trichoplein keratin filament-binding protein Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- ZSTCHQOKNUXHLZ-PIRIXANTSA-L [(1r,2r)-2-azanidylcyclohexyl]azanide;oxalate;pentyl n-[1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate;platinum(4+) Chemical compound [Pt+4].[O-]C(=O)C([O-])=O.[NH-][C@@H]1CCCC[C@H]1[NH-].C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 ZSTCHQOKNUXHLZ-PIRIXANTSA-L 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229960004539 alirocumab Drugs 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000000611 antibody drug conjugate Substances 0.000 description 1
- 229940049595 antibody-drug conjugate Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- FUKOGSUFTZDYOI-BMANNDLBSA-O beacopp protocol Chemical compound ClCCN(CCCl)P1(=O)NCCCO1.CNNCC1=CC=C(C(=O)NC(C)C)C=C1.O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3C(O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)C(O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C FUKOGSUFTZDYOI-BMANNDLBSA-O 0.000 description 1
- 229940126166 belantamab mafodotin-blmf Drugs 0.000 description 1
- 229960003270 belimumab Drugs 0.000 description 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
- 229960002707 bendamustine Drugs 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- AFTOJIAPXHGBGH-UHFFFAOYSA-N bis(2-oxopyridin-1-yl) carbonate Chemical compound C1=CC=CC(=O)N1OC(=O)ON1C=CC=CC1=O AFTOJIAPXHGBGH-UHFFFAOYSA-N 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229960003008 blinatumomab Drugs 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 229960001573 cabazitaxel Drugs 0.000 description 1
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940121420 cemiplimab Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 238000005229 chemical vapour deposition Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- XMJCOTSQMHGIPF-SNSGICDFSA-N copp protocol Chemical compound ClCCN(CCCl)P1(=O)NCCCO1.CNNCC1=CC=C(C(=O)NC(C)C)C=C1.O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 XMJCOTSQMHGIPF-SNSGICDFSA-N 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960002204 daratumumab Drugs 0.000 description 1
- 229960005029 darbepoetin alfa Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229950003468 dupilumab Drugs 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 229960004137 elotuzumab Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229950001616 erenumab Drugs 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960002027 evolocumab Drugs 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- CNZOFNMWZBNPLL-OSKRVHINSA-L flot regimen Chemical compound [Pt+4].[O-]C(=O)C([O-])=O.[NH-][C@H]1CCCC[C@@H]1[NH-].FC1=CNC(=O)NC1=O.O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)C(O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 CNZOFNMWZBNPLL-OSKRVHINSA-L 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 1
- JYEFSHLLTQIXIO-SMNQTINBSA-N folfiri regimen Chemical compound FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 JYEFSHLLTQIXIO-SMNQTINBSA-N 0.000 description 1
- PJZDLZXMGBOJRF-CXOZILEQSA-L folfirinox Chemical compound [Pt+4].[O-]C(=O)C([O-])=O.[NH-][C@H]1CCCC[C@@H]1[NH-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 PJZDLZXMGBOJRF-CXOZILEQSA-L 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960004461 interferon beta-1a Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000003046 intermediate neglect of differential overlap Methods 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 1
- 229950007752 isatuximab Drugs 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 229950003135 margetuximab Drugs 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229950007699 mogamulizumab Drugs 0.000 description 1
- 229950000720 moxetumomab pasudotox Drugs 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 229960003347 obinutuzumab Drugs 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 229950008516 olaratumab Drugs 0.000 description 1
- 244000309459 oncolytic virus Species 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- KLAKIAVEMQMVBT-UHFFFAOYSA-N p-hydroxy-phenacyl alcohol Natural products OCC(=O)C1=CC=C(O)C=C1 KLAKIAVEMQMVBT-UHFFFAOYSA-N 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229940121653 pd-1/pd-l1 inhibitor Drugs 0.000 description 1
- 108010027737 peginterferon beta-1a Proteins 0.000 description 1
- 229960001291 peginterferon beta-1a Drugs 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 229950009416 polatuzumab vedotin Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229960002633 ramucirumab Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 229950000143 sacituzumab govitecan Drugs 0.000 description 1
- ULRUOUDIQPERIJ-PQURJYPBSA-N sacituzumab govitecan Chemical compound N([C@@H](CCCCN)C(=O)NC1=CC=C(C=C1)COC(=O)O[C@]1(CC)C(=O)OCC2=C1C=C1N(C2=O)CC2=C(C3=CC(O)=CC=C3N=C21)CC)C(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN(N=N1)C=C1CNC(=O)C(CC1)CCC1CN1C(=O)CC(SC[C@H](N)C(O)=O)C1=O ULRUOUDIQPERIJ-PQURJYPBSA-N 0.000 description 1
- 229950006348 sarilumab Drugs 0.000 description 1
- 229960004540 secukinumab Drugs 0.000 description 1
- 229950011186 semaglutide Drugs 0.000 description 1
- 108010060325 semaglutide Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- 229960003708 sumatriptan Drugs 0.000 description 1
- 229940121503 tafasitamab Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- YCCHNFGPIFYNTF-UHFFFAOYSA-N tertiary cymene hydroperoxide Natural products CC1=CC=C(C(C)(C)OO)C=C1 YCCHNFGPIFYNTF-UHFFFAOYSA-N 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 239000012780 transparent material Substances 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229940049679 trastuzumab deruxtecan Drugs 0.000 description 1
- 229960001612 trastuzumab emtansine Drugs 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- 229960004914 vedolizumab Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3202—Devices for protection of the needle before use, e.g. caps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
- A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
- A61M5/3257—Semi-automatic sleeve extension, i.e. in which triggering of the sleeve extension requires a deliberate action by the user, e.g. manual release of spring-biased extension means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
- A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
- A61M5/326—Fully automatic sleeve extension, i.e. in which triggering of the sleeve does not require a deliberate action by the user
- A61M2005/3267—Biased sleeves where the needle is uncovered by insertion of the needle into a patient's body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3202—Devices for protection of the needle before use, e.g. caps
- A61M5/3204—Needle cap remover, i.e. devices to dislodge protection cover from needle or needle hub, e.g. deshielding devices
Definitions
- a sub-assembly of a medicament delivery device A sub-assembly of a medicament delivery device.
- the present disclosure generally relates to a sub-assembly of a medicament delivery device, and particularly to a sub-assembly of a medicament delivery device comprising a connector and an adapter.
- Medicament delivery devices such as pen-type manual injectors or auto-injectors are generally known for the self-administration of a medicament by patients without formal medical training.
- patients suffering from diabetes may require repeated injections of insulin, or patients may require regular injections of other types of medicaments, such as growth hormones.
- the medicament delivery devices for self-administration comprise automatic functions so that even if users are without professional training or are in an emergency situation, the users can easily and properly use the medicament delivery devices.
- distal direction refers to the direction pointing away from the dose delivery site during use of the medicament delivery device.
- distal part/end refers to the part/end of the delivery device, or the parts/ends of the members thereof, which under use of the medicament delivery device is/are located furthest away from the dose delivery site.
- proximal direction refers to the direction pointing towards the dose delivery site during use of the medicament delivery device.
- proximal part/end this refers to the part/end of the delivery device, or the parts/ends of the members thereof, which under use of the medicament delivery device is/are located closest to the dose delivery site.
- longitudinal refers to a direction extending from the proximal end to the distal end, typically along the device or components thereof in the direction of the longest extension of the device and/or component.
- transverse refers to a direction generally perpendicular to the longitudinal direction.
- circumference refers to a circumference or a circumferential direction relative to an axis, typically a central axis extending in the direction of the longest extension of the device and/or component.
- radial refers to a direction extending radially relative to the axis
- rotation refers to rotation relative to the axis.
- the subassembly comprises a tubular housing extending along a longitudinal axis between a proximal end and a distal end.
- a delivery member guard comprises a proximal portion arranged coaxially with the tubular housing. The proximal portion is configured to surround a medicament delivery member of the medicament delivery device.
- the biasing member is operably attached to the housing at one end and to the delivery member guard at the other end. The biasing member is configured to bias the delivery member guard relative to the housing from a distal position to a proximal position.
- a cap is removably attached to the proximal end of the housing. The cap comprises a distally directed surface.
- a connector comprises a proximally directed surface operably engaged with the distally directed surface of the cap and comprises a distally directed surface.
- An adapter is operably connected to the delivery member guard such that the adapter is axially immovable relative to the delivery member guard when the delivery member guard is in the distal position.
- the adapter comprises a proximally directed surface.
- the connector is rotatable around the longitudinal axis relative to the adapter between a first position where the distally directed surface of the connector is engaged with the proximally directed surface of the adapter such that the proximal portion of the delivery member guard is blocked from being biased to the proximal position and a second position where the distally directed surface of the connector is disengaged with the proximally directed surface of the adapter such that the proximal portion of the delivery member guard can be biased to the proximal position by the biasing member.
- the adapter comprises a ledge extending from a wall of the proximal portion of the delivery member guard.
- the ledge comprises the proximally directed surface of the adapter.
- the adapter comprises a ring-shaped body.
- the adapter comprises a ledge extending from an inner surface of the ring-shaped body.
- the ring-shaped body comprises a distally directed surface.
- the proximal portion of the delivery member guard comprises a proximally directed surface engaged with the distally directed surface of the ring-shaped body.
- the adapter comprises an engaging member and the housing comprises a counter engaging member engaged with the engaging member such that the adapter is rotationally immovable relative to the housing when the delivery member guard is in the distal position.
- the engaging member and the counter engaging member form at least one of a rib-and-rib engagement, a rib-and-recess engagement, and a rib-and-cut-out engagement.
- the adapter comprises an engaging member and the cap comprises a counter engaging member engaged with the engaging member such that the adapter is rotationally immovable relative to the cap when the delivery member guard is in the distal position.
- the engaging member comprises a noncircular cross-section perpendicular to the longitudinal axis
- the counter engaging member comprises a counter non-circular cross-section perpendicular to the longitudinal axis
- the engaging member of the adapter is an inner circumferential surface of the ring-shaped body of the adapter.
- the connector comprises a body.
- the connector comprises a ledge extending from an inner surface of the body of the connector towards the longitudinal axis.
- the ledge comprises the distally directed surface of the connector.
- the body of the connector is the ring-shaped body.
- the sub-assembly comprises a delivery member cover assembly.
- the delivery member cover assembly comprises a tubular outer cap and a clutch member.
- the cap is at least partially surrounded by the tubular outer cap.
- the clutch member is rotationally fixed to the cap and positioned longitudinally between the tubular outer cap and the delivery member guard.
- the clutch member comprises a clutch biasing member, the clutch member being axially movable relative to the outer cap from a relaxed position to a tensioned position when the delivery member guard is moved from the distal position to the proximal position.
- the tubular outer cap is axially fixed with and rotatable relative to the cap.
- the tubular outer cap comprises an engaging member and the clutch member comprises a counter engaging member.
- the engaging member is adjacent to the counter engaging member when the clutch biasing member is in the relaxed position.
- the connector is the tubular outer cap.
- the connector is positioned longitudinally between the tubular outer cap and the delivery member guard and is positioned at least partially between the tubular outer cap and the clutch member.
- the connector is rotatable relative to the clutch member.
- the connector comprises a rotational engaging member.
- the outer cap comprises a counter rotational engaging member adjacent to the rotational engaging member such that the connector is manually rotated from the first position to the second position via a rotation of the tubular outer cap relative to the cap.
- the engaging member of the tubular outer cap is the counter rotational engaging member.
- the rotational engaging member of the connector is a counter protrusion.
- the rotational engaging member and the counter rotational engaging member form a ratchet engagement such that the connector is only rotationally fixed to the tubular outer cap in one rotational direction.
- the clutch member comprises a proximal portion and a distal portion.
- the clutch biasing member is longitudinally positioned between the proximal portion and the distal portion.
- the proximal portion is releasably engaged with a distally directed surface on the inner surface of the tubular outer cap.
- the adapter is the distal portion of the clutch member.
- the counter engaging members of the clutch member is a counter protrusion.
- the counter protrusion extends radially outwardly relative to the longitudinal axis from an outer surface of the cap.
- the counter engaging member of the clutch member is arranged on an outer surface of the distal portion.
- the counter engaging member comprises a flexible arm extending partially around the longitudinal axis.
- the delivery member guard is partially arranged within the housing.
- the tubular proximal portion of the delivery member guard is arranged telescopically relative to the proximal end of the housing.
- the biasing member is a spring.
- the housing comprises a proximally directed surface.
- the delivery member guard comprises a distally directed surface.
- the spring extends between a first end engaged with the proximally directed surface of the housing and a second end engaged with the distally directed surface of the delivery member guard.
- the sub-assembly is used in a medicament delivery device comprising a multiple-chamber medicament container arranged within the carrier.
- the medicament container of the medicament delivery device is a syringe, a cartridge or a collapsible bag.
- the medicament container of the medicament delivery device is made of glass material or plastic material.
- the medicament delivery device is an injection device, an inhalation device, or a medical sprayer.
- the medicament delivery device is an autoinjector.
- the medicament delivery member is an injection needle or a spray nozzle.
- the medicament delivery devices described herein can be used for the treatment and/or prophylaxis of one or more of many different types of disorders.
- exemplary disorders include, but are not limited to: rheumatoid arthritis, inflammatory bowel diseases (e.g. Crohn’s disease and ulcerative colitis), hypercholesterolaemia, diabetes (e.g. type 2 diabetes), psoriasis, migraines, multiple sclerosis, anaemia, lupus, atopic dermatitis, asthma, nasal polyps, acute hypoglycaemia, obesity, anaphylaxis and allergies.
- Exemplary types of drugs that could be included in the medicament delivery devices described herein include, but are not limited to, small molecules, hormones, cytokines, blood products, antibodies, antibody-drug conjugates, bispecific antibodies, proteins, fusion proteins, peptibodies, polypeptides, pegylated proteins, protein fragments, protein analogues, protein variants, protein precursors, chimeric antigen receptor T cell therapies, cell or gene therapies, oncolytic viruses, or immunotherapies and/or protein derivatives.
- Exemplary drugs that could be included in the medicament delivery devices described herein include, but are not limited to (with non-limiting examples of relevant disorders in brackets): etanercept (rheumatoid arthritis, inflammatory bowel diseases (e.g.
- evolocumab hypercholesterolaemia
- exenatide type 2 diabetes
- secukinumab psoriasis
- erenumab mimerase
- alirocumab rheumatoid arthritis
- methotrexate amethopterin
- tocilizumab rheumatoid arthritis
- interferon beta-1 a multiple sclerosis
- sumatriptan miraines
- adalimumab rheumatoid arthritis
- darbepoetin alfa anaemia
- sarilumab rheumatoid arthritis
- semaglutide type 2 diabetes, obesity
- dupilumab atopic dermatitis, asthma, nasal polyps, allergies
- glucagon glucagon
- ipilimumab nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, cemiplimab, rituximab, trastuzumab, ado-trastuzumab emtansine, fam-trastuzumab deruxtecan-nxki, pertuzumab, transtuzumab-pertuzumab, alemtuzumab, belantamab mafodotin-blmf, bevacizumab, blinatumomab, brentuximab vedotin, cetuximab, daratumumab, elotuzumab, gemtuzumab ozogamicin, 90- Yttrium- ibritumomab tiuxetan, isatuxim
- compositions including, but not limited to, any drug described herein are also contemplated for use in the medicament delivery devices described herein, for example pharmaceutical formulations comprising a drug as listed herein (or a pharmaceutically acceptable salt of the drug) and a pharmaceutically acceptable carrier.
- pharmaceutical formulations comprising a drug as listed herein (or a pharmaceutically acceptable salt of the drug) may include one or more other active ingredients, or may be the only active ingredient present.
- Exemplary drugs that could be included in the medicament delivery devices described herein include, but are not limited to, an immuno-oncology or bio-oncology medications such as immune checkpoints, cytokines, chemokines, clusters of differentiation, interleukins, integrins, growth factors, enzymes, signaling proteins, pro-apoptotic proteins, anti-apoptotic proteins, T-cell receptors, B-cell receptors, or costimulatory proteins.
- an immuno-oncology or bio-oncology medications such as immune checkpoints, cytokines, chemokines, clusters of differentiation, interleukins, integrins, growth factors, enzymes, signaling proteins, pro-apoptotic proteins, anti-apoptotic proteins, T-cell receptors, B-cell receptors, or costimulatory proteins.
- Exemplary drugs that could be included in the medicament delivery devices described herein include, but are not limited to, those exhibiting a proposed mechanism of action, such as HER-2 receptor modulators, interleukin modulators, interferon modulators, CD38 modulators, CD22 modulators, CCR4 modulators, VEGF modulators, EGFR modulators, CD79b modulators, Trop-2 modulators, CD52 modulators, BCMA modulators, PDGFRA modulators, SLAMF7 modulators, PD-1/PD-L1 inhibitors/modulators, B-lymphocyte antigen CD19 inhibitors, B-lymphocyte antigen CD20 modulators, CD3 modulators, CTLA-4 inhibitors, TIM-3 modulators, VISTA modulators, INDO inhibitors, LAG3 (CD223) antagonists, CD276 antigen modulators, CD47 antagonists, CD30 modulators, CD73 modulators, CD66 modulators, CDw137 agonists, CD158 modulators, CD27 modulators, CD58 modulators, CD80 modulators, CD33 modulators,
- Exemplary drugs that could be included in the medicament delivery devices described herein include, but are not limited to, a multi-medication treatment regimen such as AC, Dose- Dense AC, TCH, GT, EC, TAC, TC, TCHP, CMF, FOLFOX, mFOLFOX6, mFOLFOX7, FOLFCIS, CapeOx, FLOT, DCF, FOLFIRI, FOLFIRINOX, FOLFOXIRI, IROX, CHOP, R- CHOP, RCHOP-21 , Mini-CHOP, Maxi-CHOP, VR-CAP, Dose-Dense CHOP, EPOCH, Dose- Adjusted EPOCH, R-EPOCH, CODOX-M, IVAC, HyperCVAD, R-HyperCVAD, SC-EPOCH- RR, DHAP, ESHAP, GDP, ICE, MINE, CEPP, CDOP, GemOx, CEOP, CEPP, CHOEP, CHP, GCVP, D
- Exemplary drugs that could be included in the medicament delivery devices described herein include, but are not limited to, those used for chemotherapy, such as an alkylating agent, plant alkaloid, antitumor antibiotic, antimetabolite, or topoisomerase inhibitor, enzyme, retinoid, or corticosteroid.
- chemotherapy such as an alkylating agent, plant alkaloid, antitumor antibiotic, antimetabolite, or topoisomerase inhibitor, enzyme, retinoid, or corticosteroid.
- Exemplary chemotherapy drugs include, by way of example but not limitation, 5-fluorouracil, cisplatin, carboplatin, oxaliplatin, doxorubicin, daunorubicin, idarubicin, epirubicin, paclitaxel, docetaxel, cyclophosphamide, ifosfamide, azacitidine, decitabine, bendamustine, bleomycin, bortezomib, busulfan, cabazitaxel, carmustine, cladribine, cytarabine, dacarbazine, etoposide, fludarabine, gemcitabine, irinotecan, leucovorin, melphalan, methotrexate, pemetrexed, mitomycin, mitoxantrone, temsirolimus, topotecan, valrubicin, vincristine, vinblastine, or vinorelbine.
- Fig. 1 schematically shows a perspective view of a sub-assembly of the invention in an initial state
- Fig. 2 schematically shows a perspective view of the sub-assembly of Fig. 1 in a ready-to- be-used state
- Fig. 3 schematically shows a perspective view of another example of the sub-assembly of the invention in an initial state
- Fig. 4 schematically shows a perspective view of the sub-assembly of Fig. 3 in an initial state
- Fig. 5 schematically shows a perspective view of components of the sub-assembly of Fig. 1 .
- Fig. 6 schematically shows a perspective view of components of the sub-assembly of Fig. 3.
- Figs 7A-E schematically show perspective views of an operation sequence of the subassembly of Fig. 1 ;
- Figs 8A-B schematically show perspective views of an operation sequence of the subassembly of Fig. 3;
- Fig. 9 schematically shows a perspective view of a delivery member guard of the subassembly of the invention and a cap assembly of the sub-assembly of the invention
- Figs 10-11 schematically show perspective views of the cap assembly of Fig. 9;
- Fig. 12 schematically shows a perspective view of a cap of the cap assembly of Fig. 9;
- Fig. 13 schematically shows a perspective view of a clutch member of the sub-assembly of the invention
- Figs 14-15 schematically show a perspective view of the cap assembly of Fig. 9 with the clutch member of Fig. 13.
- Figs 1-15 illustrate many examples of a sub-assembly of a medicament delivery device.
- the sub-assembly comprises a tubular housing 1 ; 1 a delivery member guard 2; 2’, a biasing member, a cap 31 , a connector 5; 5’ and an adapter 6; 6’.
- the tubular housing 1 ; 1 ’ extends along a longitudinal axis L between a proximal end and a distal end.
- the tubular housing 1 ; 1 ' is configured to receive a medicament container of the medicament delivery device.
- the tubular housing 1 ; 1 ' comprises an observation window so that a user of the medicament delivery device can check the condition of the medicament within the medicament container before use.
- the window can be a transparent portion or an aperture in a wall of the tubular housing 1 ; 1'.
- the housing can be made of transparent material so that the window is no longer necessary for the user to observe the medicament.
- the tubular housing 1 ; 1 ' has a rectangular cross-section perpendicular to the longitudinal axis L, so that the medicament delivery device can be prevented from rolling on a flat surface. It should be noted that such functionality can be obtained by forming the tubular housing 1 ; 1 ' in any shape that has a non-circular cross-section perpendicular to the longitudinal axis L.
- the tubular housing can be formed by multiple components, or the tubular housing can be formed by a single component, dependent on the design.
- the delivery member guard 2; 2’ comprises a proximal portion 20; 20’ arranged coaxially with the tubular housing 1 ; 1 ’.
- the proximal portion 20; 20’ is configured to surround a medicament delivery member of the medicament delivery device.
- the proximal portion 20; 20’ can be tubular, or it can be formed by multiple proximally extending arms.
- the delivery member guard 2; 2’ is partially arranged within the housing.
- the tubular proximal portion 20; 20’ of the delivery member guard 2; 2’ is arranged telescopically relative to the proximal end of the housing 1 ; 1 ’, as shown in Figs 1-4.
- the delivery member guard at least partially surrounds a proximal portion of the tubular housing.
- the biasing member is operably attached to the tubular housing 1 ; 1 ’ at one end and to the delivery member guard 2; 2’ at the other end.
- the biasing member is configured to bias the delivery member guard 2; 2’ relative to the housing from a distal position to a proximal position.
- the biasing member can be a spring, e.g., a compression spring, a tension spring, a band spring; or a flexible arm.
- the tubular housing 1 comprises a proximally directed surface and the delivery member guard comprises a distally directed surface.
- the biasing member extends between a first end that is engaged with the proximally directed surface of the housing, and a second end that is engaged with the distally directed surface of the delivery member guard.
- the cap 31 is removably attached to the proximal end of the housing 1 ; 1 '.
- the cap 31 comprises a distally directed surface 311 .
- the cap 31 is configured to seal a medicament delivery member, e.g., an injection needle or a spray nozzle, of the medicament delivery device.
- the cap 31 is configured to be removed from the housing via a rotation of the cap 31 around the longitudinal axis L of the tubular housing 1 and relative to the tubular housing.
- the cap 31 is engaged with the tubular housing 1 via a threaded engagement or a bayonet engagement.
- the cap is configured to be removed from the tubular housing via a linear movement relative to the housing.
- the cap is configured to be pulled by a user of the medicament delivery device.
- the connector 5; 5’ comprises a proximally directed surface 501 ; 501 ’ operably engaged with the distally directed surface 311 of the cap 31 and comprises a distally directed surface 51 a; 51 a’. Therefore, the connector 5; 5’ is axially immovable relative to the cap 31 in the proximal direction of the tubular housing 1 ; 1 ’.
- the connector 5; 5’ comprises a body.
- the connector 5’ comprises a ledge 51 ’ extending from an inner surface of the body of the connector 5’ towards the longitudinal axis L, as shown in Fig. 6.
- the ledge 51 ’ comprises the distally directed surface 51 a’ of the connector 5’.
- the ledge 51 extends from an outer surface of the body of the connector 5 away from the longitudinal axis, as shown in Fig. 5.
- the ledge 51 comprises the distally directed surface 51 a of the connector 5.
- the body of the connector 5; 5’ is generally cylindrical. In a preferred example, the body of the connector 5’ is a ring-shaped body.
- the adapter 6; 6’ is operably connected to the delivery member guard 2; 2’ such that the adapter s; 6’ is axially immovable relative to the delivery member guard 2; 2’ when the delivery member guard 2; 2 is in the distal position.
- the adapter 6; 6’ comprises a distally directed surface engaged with a proximally directed surface of the delivery member guard 2; 2’ directly, as shown in Figs 7A-7D and Fig. 8A.
- the adapter is an integral part of the proximal portion of the delivery member guard.
- the adapter 6; 6’ comprises a proximally directed surface 60a; 60a’ engaged with the distally directed surface 51 a; 51 a’ of the connector 5; 5’ when the connector 5; 5’ is in a first position.
- the delivery member guard 2; 2’ is blocked from moving in the proximal direction relative to the tubular housing 1 .
- the proximally directed surface 60a; 60a’ of the adapter 6; 6’ is disengaged from the distally directed surface 51 a; 51 a’ of the connector 5; 5’ when the connector 5; 5’ is in a second position such that the proximal portion 20; 20’ of the delivery member guard 2; 2’ can be biased to the proximal position by the biasing member.
- the adapter is an integral part of the proximal portion of the delivery member guard
- the adapter comprises a ledge extending from a wall of the proximal portion of the delivery member guard.
- the ledge comprises the proximally directed surface of the adapter.
- the adapter 6; 6’ is an independent component separate from the delivery member guard, as shown in Figs 5-6.
- the adapter 6; 6’ comprises a ring-shaped body, as shown in Figs 5-6.
- ring-shaped body used in this description means that the body comprises a wall enclosing the longitudinal axis L.
- the ring-shaped body comprises the distally directed surface engaged with the proximally directed surface of the delivery member guard when the delivery member guard is in the distal position.
- the distally directed surface of the adapter 6; 6’ is defined by the distal end edge of the ring-shaped body, and the proximal directed surface of the delivery member guard 2; 2’ is defined by the proximal end edge of the proximal portion 20; 20’.
- the connector 5; 5' is configured to be rotated relative to the adapter 6; 6 around the longitudinal axis L between the first position and the second position.
- the connector 5 is configured to be rotated relative to the tubular housing 1 around the longitudinal axis L between the first position and the second position.
- the adapter 6' is configured to rotate relative to the tubular housing 1 around the longitudinal axis L between the first position of the connector s' and the second position of the connector 5'.
- the adapter s; 6’ comprises a ledge 60; 60 extending from an inner surface of the ring-shaped body.
- the ledge comprises the proximally directed surface 60a; 60a’ of the adapter 6; 6’.
- the proximally directed surface 60a; 60a’ of the adapter s; 6’ is engaged with the distally directed surface 51 a; 51 a’ of the connector 5; 5’ when the connector 5; 5’ is in the first position.
- the proximally directed surface 501 of the connector 5 is directly engaged with the distally directed surface 311 of the cap 31 , as shown in Fig. 8A.
- the proximally directed surface 501 ' of the connector 5' is indirectly engaged with a tubular outer cap 30 which is engaged with the distally directed surface 311 of the cap 31 , as shown in Fig. 7A.
- the connector 5 is accessible to the user of the medicament delivery device, as shown in Figs 1-2.
- the connector 5 is the tubular outer cap 30 of the medicament delivery device.
- the connector 5 is configured to be manually rotated by the user from the first position to the second position when the user plans to use the medicament delivery device.
- the delivery member guard 2 when the user rotates the connector 5 to the second position, as the proximally directed surface 60a of the adapter 6 is disengaged from the distally directed surface 51 a of the connector 5 (as shown in Fig. 8B), the delivery member guard 2 is biased to its proximal position by the biasing member. Therefore, an indication can be provided to the user that the device is ready to be used.
- the proximal portion of the delivery member guard comprises a color different to the tubular housing and the cap, and/or a mark for indication purposes.
- the tubular housing may be white, and the cap may be red, in this example, the proximal portion of the delivery member guard can be yellow or green.
- the adapter 6 comprises an engaging member 61 and the housing comprises a counter engaging member 11 engaged with the engaging member 61 , as shown in Figs 1-2, such that the adapter 6 is rotationally immovable relative to the housing 1 when the delivery member guard 2 is in the distal position. Therefore, the user can only disengage the proximally directed surface 60a of the adapter 6 from the distally directed surface 51 a of the connector 5 by rotating the connector 5.
- the connector 5 is the tubular outer cap 30 of the medicament delivery device
- the rotation of the connector from the first position to the second position is a part of the action causing the cap to be removed from the tubular housing 1 .
- the engaging member 61 of the adapter 6 and the counter engaging member 11 of the tubular housing 1 form at least one of a rib-and-rib engagement, a rib-and- recess engagement, and a rib-and-cut-out engagement.
- the adapter is configured to be manually rotated by the user relative to the connector around the longitudinal axis L of the tubular housing.
- the connector 5' is covered by the tubular outer cap 30 of the medicament delivery device, as shown in Fig. 3 and Fig. 7 A, such that the user cannot access to the connector 5’ and therefore, the connector 5’ cannot be manually rotated by the user.
- the adapter 6’ comprises an engaging member 61 ’ and the cap 31 comprises a counter engaging member 312 engaged with the engaging member 61 ’ (as shown in Fig. 7B) such that the adapter 6’ is rotationally immovable relative to the cap 31 when the delivery member guard 2’ is in the distal position.
- the engaging member 61 ’ of the adapter and the counter engaging member of the cap forme a rib-and-rib engagement, a rib-and-recess engagement, or a rib-and-cut-out engagement.
- the engaging member 61 ’ of the adapter 6’ comprises a non-circular cross-section perpendicular to the longitudinal axis L
- the counter engaging member 312 of the cap 31 comprises a counter non-circular cross-section perpendicular to the longitudinal axis L, as shown in Fig. 7B.
- the engaging member 61 ’ of the adapter 6’ is the inner circumferential surface 61 ’ of the ringshaped body of the adapter 6’.
- Figs 7A-7E will also be used to explain another example where the connector 5’ is configured to be manually rotated by the user via the outer cap 30. This example will be explained later.
- the sub-assembly comprises a delivery member cover assembly 3.
- the delivery member cover assembly 3 comprises the tubular outer cap 30 and a clutch member 32.
- the cap 31 is at least partially surrounded by the tubular outer cap 30.
- the clutch member 32 is rotationally fixed to the cap 31 and positioned longitudinally between the tubular outer cap 30 and the delivery member guard 2; 2’.
- the clutch member 32 comprises a clutch biasing member 320.
- the clutch member 32 is axially movable relative to the outer cap 30 from a relaxed position to a tensioned position when the delivery member guard 2; 2’ is moved from the distal position to the proximal position.
- the tubular outer cap 30 is axially fixed with and rotatable relative to the cap 31 .
- the tubular outer cap 30 comprises an engaging member 301 and the clutch member 32 comprises a counter engaging member 33.
- the engaging member 301 is adjacent to the counter engaging member 33 when the clutch biasing member 320 is in the related position.
- the connector 5 is the tubular outer cap 30, the connector 5 is rotatable relative to the cap 31 when the clutch biasing member is in the tensioned position.
- the connector 5 is axially immovable relative to the cap 31 by the distally directed surface 311 of the cap 31 and the proximally directed surface 501 of the connector 5.
- the connect 5 can freely rotate relative to the cap 31 .
- the connector 5 comprises a hook 302 positioned within an annular groove of the cap 31 .
- the hook 302 comprises the proximally directed surface 501 of the connector 5.
- the edge of the annular groove of the cap 31 comprises the distally directed surface 311 , as shown in Fig.
- the engagement between cap 31 and the clutch member 32 can be a rib-and-rib engagement, a rib-and-recess engagement, or a rib-and-cut-out engagement.
- an engaging member 322a of the clutch member comprises a non-circular cross-section perpendicular to the longitudinal axis L.
- the counter engaging member 312 of the cap 31 is a counter non-circular cross-section perpendicular to the longitudinal axis L, as shown in Figs 12-13.
- the engaging member 301 of the tubular outer cap 30 is a protrusion extending from an inner wall of the tubular outer cap 30 towards the longitudinal axis L.
- the engaging member 301 is a rack.
- the engaging member 301 is a set of ratchet teeth.
- the counter engaging member 33 of the clutch member 32 is a counter protrusion 33 extending radially outwardly relative to the longitudinal axis L from an outer surface of the cap 31 .
- the counter engaging member 33 comprises a flexible arm 331 extending partially around the longitudinal axis L, as shown in Fig. 13.
- the user can get an audible and/or a tactile indication if the user turns the tubular outer cap 30 in the direction that cannot result in removal of the cap 31 .
- the clutch member 32 comprises a proximal portion 321 and a distal portion 322.
- the clutch biasing member 320 is longitudinally positioned between the proximal portion 321 and the distal portion 322, as shown in Fig. 9.
- the proximal portion 321 is releasably engaged with a distally directed surface on the inner surface of the tubular outer cap 30.
- the counter engaging member 33 of the clutch member 32 is arranged on an outer surface of the distal portion 322.
- the adapter 6’ is the distal portion 322 of the clutch member 32, as shown in Fig. 7A and Fig. 7D.
- the connector 5’ is an independent component from the tubular outer cap 30
- the connector 5’ is positioned longitudinally between the tubular outer cap 30 and the delivery member guard 2’ and is positioned at least partially between the tubular outer cap 30 and the clutch member 32, as shown in Fig. 7A.
- the connector 5’ is rotatable relative to the clutch member 32.
- the connector 5’ comprises a rotational engaging member 52’ configured to engage with a counter rotational engaging member 301 of the tubular outer cap 30. Therefore, the connector 5’ is manually rotated from the first position to the second position via a rotation of the tubular outer cap 30 relative to the cap 31 .
- the counter rotational engaging member 301 of the tubular outer cap 30 is the engaging member 301 of the tubular outer cap 30.
- the clutch biasing member 320 when the clutch biasing member 320 is in the tensioned position, the counter engaging member 33 of the clutch member 32 is spaced apart from the engaging member 301 of the tubular outer cap 30, and the rotational engaging member 52’ of the connector 5’ is adjacent to the engaging member 301 of the tubular outer cap 30. Therefore, when the user rotates the tubular outer cap 30 relative to the tubular housing 1 around the longitudinal axis L, the connector 5’ is also rotated from its first position to the second position (as shown in Fig. 7D with the arrow R1).
- the adapter 6’ namely, the distal portion 322 of the clutch member 32 in this example, is moved in the proximal position relative to the tubular outer cap 30 by the biased delivery member guard 2’. Therefore, when the delivery member guard is in the proximal position, the counter engaging member 33 of the clutch member 32 is adjacent to the engaging member 301 of the tubular outer cap 30, as mentioned above. The user can remove the cap 31 by further rotating the tubular outer cap 30 (as shown in Fig. 7E with the arrow R2).
- the rotational engaging member 52’ of the connector 5’ is a protrusion.
- the rotational engaging member 52’ and the counter rotational engaging member 301 form a ratchet engagement such that the connector is only rotationally fixed to the tubular outer cap in one rotational direction.
- the rotational engaging member 52’ of the connector 5' may comprise a flexible arm extending in the radial direction such that an audible and/or tactile indication is generated when the user rotates the tubular outer cap 30 in the direction that will not result in the removal of the cap 31 .
- the clutch member 32 is configured to control the cap removal in a specific order, namely, the cap 31 should not be removed before the delivery member guard moves to the proximal position.
- the proximal movement of the delivery member guard and the cap removal are all linked to at least one specific function.
- the proximal movement of the delivery member guard may be configured to trigger a mixing operation between multiple chambers of the medicament container, and the cap removal may be configured to cause a medicament delivery member to be mounted to the medicament container.
- the mixing operation may not work properly, as the increased pressure within the medicament container will cause the medicament to be expelled rather than enter into another chamber.
- the proximal movement of the delivery member guard is configured to be a tamper-evident that indicates the user that the sterilization of the medicament delivery member is changed (as the cap has been turned).
- the clutch member can be moved from the first position to the second position relative to the adapter during the cap removal.
- the housing of the medicament delivery device may be provided with (i.e., molded in, molded with) a compound featuring persistently antimicrobial, antifungal, and/or antiviral properties.
- a compound featuring persistently antimicrobial, antifungal, and/or antiviral properties may be applied to the molded (i.e., finished) components through secondary processes (e.g., chemical vapor deposition), spraying, or dipping processes.
- a sub-assembly of a medicament delivery device comprising: a tubular housing (1 ; 1 ’) extending along a longitudinal axis (L) between a proximal end and a distal end; a delivery member guard (2; 2’) comprising a proximal portion (20; 20’) arranged coaxially with the tubular housing (1); wherein the proximal portion (20; 20’) is configured to surround a medicament delivery member of the medicament delivery device; a biasing member operably attached to the housing (1 ; 1 ’) at one end and to the delivery member guard (2; 2’) at the other end; wherein the biasing member is configured to bias the delivery member guard (2; 2’) relative to the housing from a distal position to a proximal position; a cap (31) removably attached to the proximal end of the housing (1 ; 1 ’); wherein the cap (31) comprises a distally directed surface (311); a connector (5;
- the adapter comprises a ringshaped body; wherein the adapter comprises a ledge extending from an inner surface of the ring-shaped body; wherein the ring-shaped body comprises a distally directed surface; and wherein the proximal portion of the delivery member guard comprises a proximally directed surface engaged with the distally directed surface of the ring-shaped body.
- the connector comprises a body; wherein the connector comprises a ledge extending from an inner surface of the body of the connector towards the longitudinal axis; and wherein the ledge comprises the distally directed surface of the connector.
- the housing comprises a proximally directed surface; wherein the delivery member guard comprises a distally directed surface; and wherein the biasing member is a spring extending between a first end engaged with the proximally directed surface of the housing and a second end engaged with the distally directed surface of the delivery member guard.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Environmental & Geological Engineering (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
A sub-assembly of a medicament delivery device, the sub-assembly comprising: a tubular housing, a delivery member guard arranged coaxially with the tubular housing, a biasing member configured to bias the delivery member guard relative to the housing from a distal position to a proximal position, a cap removably attached to the proximal end of the housing, a connector, and an adapter operably connected to the delivery member guard such that the adapter is axially immovable relative to the delivery member guard when the delivery member guard is in the distal position; wherein the adapter comprises a proximally directed surface. The connector is rotatable around the longitudinal axis relative to the adapter between a first position where the distally directed surface of the connector is adjacent to the proximally directed surface of the adapter such that the proximal portion of the delivery member guard is blocked from being biased to the proximal position and a second position where the distally directed surface of the connector is offset relative to the proximally directed surface of the adapter such that the proximal portion of the delivery member guard can be biased to the proximal position by the biasing member.
Description
TITLE
A sub-assembly of a medicament delivery device.
TECHNICAL FIELD
The present disclosure generally relates to a sub-assembly of a medicament delivery device, and particularly to a sub-assembly of a medicament delivery device comprising a connector and an adapter.
BACKGROUND
Medicament delivery devices such as pen-type manual injectors or auto-injectors are generally known for the self-administration of a medicament by patients without formal medical training. For example, patients suffering from diabetes may require repeated injections of insulin, or patients may require regular injections of other types of medicaments, such as growth hormones.
It is an advantage when the medicament delivery devices for self-administration comprise automatic functions so that even if users are without professional training or are in an emergency situation, the users can easily and properly use the medicament delivery devices.
Even though many of the devices on the market, as well as the ones described above, have their respective advantages, there is still room for improvement.
SUMMARY
The invention is defined by the appended claims, to which reference should now be made.
In the present disclosure, when the term “distal direction” is used, this refers to the direction pointing away from the dose delivery site during use of the medicament delivery device. When the term “distal part/end” is used, this refers to the part/end of the delivery device, or the parts/ends of the members thereof, which under use of the medicament delivery device is/are located furthest away from the dose delivery site. Correspondingly, when the term “proximal direction” is used, this refers to the direction pointing towards the dose delivery site during use of the medicament delivery device. When the term “proximal part/end” is used, this refers to the part/end of the delivery device, or the parts/ends of the members thereof, which under use of the medicament delivery device is/are located closest to the dose delivery site.
Further, the term “longitudinal”, “longitudinally”, “axially” or “axial” refer to a direction extending from the proximal end to the distal end, typically along the device or components thereof in the direction of the longest extension of the device and/or component.
Similarly, the terms “transverse”, “transversal” and “transversally” refer to a direction generally perpendicular to the longitudinal direction.
Further, the terms “circumference”, “circumferential”, or “circumferentially” refer to a circumference or a circumferential direction relative to an axis, typically a central axis extending in the direction of the longest extension of the device and/or component. Similarly, “radial” or “radially” refer to a direction extending radially relative to the axis, and “rotation”, “rotational” and “rotationally” refer to rotation relative to the axis.
There is hence provided a sub-assembly of a medicament delivery device. The subassembly comprises a tubular housing extending along a longitudinal axis between a proximal end and a distal end. A delivery member guard comprises a proximal portion arranged coaxially with the tubular housing. The proximal portion is configured to surround a medicament delivery member of the medicament delivery device. The biasing member is operably attached to the housing at one end and to the delivery member guard at the other end. The biasing member is configured to bias the delivery member guard relative to the housing from a distal position to a proximal position. A cap is removably attached to the proximal end of the housing. The cap comprises a distally directed surface. A connector comprises a proximally directed surface operably engaged with the distally directed surface of the cap and comprises a distally directed surface. An adapter is operably connected to the delivery member guard such that the adapter is axially immovable relative to the delivery member guard when the delivery member guard is in the distal position. The adapter comprises a proximally directed surface. The connector is rotatable around the longitudinal axis relative to the adapter between a first position where the distally directed surface of the connector is engaged with the proximally directed surface of the adapter such that the proximal portion of the delivery member guard is blocked from being biased to the proximal position and a second position where the distally directed surface of the connector is disengaged with the proximally directed surface of the adapter such that the proximal portion of the delivery member guard can be biased to the proximal position by the biasing member.
Preferably, according to another embodiment, the adapter comprises a ledge extending from a wall of the proximal portion of the delivery member guard.
Preferably, according to another embodiment, the ledge comprises the proximally directed surface of the adapter.
Alternatively, according to another embodiment, the adapter comprises a ring-shaped body.
Preferably, according to another embodiment, the adapter comprises a ledge extending from an inner surface of the ring-shaped body.
Preferably, according to another embodiment, the ring-shaped body comprises a distally directed surface.
Preferably, according to another embodiment, the proximal portion of the delivery member guard comprises a proximally directed surface engaged with the distally directed surface of the ring-shaped body.
Preferably, according to another embodiment, the adapter comprises an engaging member and the housing comprises a counter engaging member engaged with the engaging member such that the adapter is rotationally immovable relative to the housing when the delivery member guard is in the distal position.
Preferably, according to another embodiment, the engaging member and the counter engaging member form at least one of a rib-and-rib engagement, a rib-and-recess engagement, and a rib-and-cut-out engagement.
Alternatively, according to another embodiment, the adapter comprises an engaging member and the cap comprises a counter engaging member engaged with the engaging member such that the adapter is rotationally immovable relative to the cap when the delivery member guard is in the distal position.
Preferably, according to another embodiment, the engaging member comprises a noncircular cross-section perpendicular to the longitudinal axis, and the counter engaging member comprises a counter non-circular cross-section perpendicular to the longitudinal axis.
Preferably, according to another embodiment, the engaging member of the adapter is an inner circumferential surface of the ring-shaped body of the adapter.
Preferably, according to another embodiment, the connector comprises a body. The connector comprises a ledge extending from an inner surface of the body of the connector towards the longitudinal axis.
Preferably, according to another embodiment, the ledge comprises the distally directed surface of the connector.
Preferably, according to another embodiment, the body of the connector is the ring-shaped body.
Preferably, according to another embodiment, the sub-assembly comprises a delivery member cover assembly.
Preferably, according to another embodiment, the delivery member cover assembly comprises a tubular outer cap and a clutch member.
Preferably, according to another embodiment, the cap is at least partially surrounded by the tubular outer cap.
Preferably, according to another embodiment, the clutch member is rotationally fixed to the cap and positioned longitudinally between the tubular outer cap and the delivery member guard.
Preferably, according to another embodiment, the clutch member comprises a clutch biasing member, the clutch member being axially movable relative to the outer cap from a relaxed position to a tensioned position when the delivery member guard is moved from the distal position to the proximal position.
Preferably, according to another embodiment, the tubular outer cap is axially fixed with and rotatable relative to the cap.
Preferably, according to another embodiment, the tubular outer cap comprises an engaging member and the clutch member comprises a counter engaging member. Preferably, according to another embodiment, the engaging member is adjacent to the counter engaging member when the clutch biasing member is in the relaxed position.
Preferably, according to another embodiment, the connector is the tubular outer cap.
Preferably, according to another embodiment, the connector is positioned longitudinally between the tubular outer cap and the delivery member guard and is positioned at least partially between the tubular outer cap and the clutch member.
Preferably, according to another embodiment, the connector is rotatable relative to the clutch member.
Preferably, according to another embodiment, the connector comprises a rotational engaging member. The outer cap comprises a counter rotational engaging member adjacent to the rotational engaging member such that the connector is manually rotated from the first position to the second position via a rotation of the tubular outer cap relative to the cap.
Preferably, according to another embodiment, the engaging member of the tubular outer cap is the counter rotational engaging member.
Preferably, according to another embodiment, the rotational engaging member of the connector is a counter protrusion. The rotational engaging member and the counter
rotational engaging member form a ratchet engagement such that the connector is only rotationally fixed to the tubular outer cap in one rotational direction.
Preferably, according to another embodiment, the clutch member comprises a proximal portion and a distal portion. The clutch biasing member is longitudinally positioned between the proximal portion and the distal portion. The proximal portion is releasably engaged with a distally directed surface on the inner surface of the tubular outer cap.
Preferably, according to another embodiment, the adapter is the distal portion of the clutch member.
Preferably, according to another embodiment, the counter engaging members of the clutch member is a counter protrusion. The counter protrusion extends radially outwardly relative to the longitudinal axis from an outer surface of the cap.
Preferably, according to another embodiment, the counter engaging member of the clutch member is arranged on an outer surface of the distal portion.
Preferably, according to another embodiment, the counter engaging member comprises a flexible arm extending partially around the longitudinal axis.
Preferably, according to another embodiment, the delivery member guard is partially arranged within the housing.
Preferably, according to another embodiment, the tubular proximal portion of the delivery member guard is arranged telescopically relative to the proximal end of the housing.
Preferably, according to another embodiment, the biasing member is a spring.
Preferably, according to another embodiment, the housing comprises a proximally directed surface. The delivery member guard comprises a distally directed surface.
Preferably, according to another embodiment, the spring extends between a first end engaged with the proximally directed surface of the housing and a second end engaged with the distally directed surface of the delivery member guard.
Preferably, according to another embodiment, the sub-assembly is used in a medicament delivery device comprising a multiple-chamber medicament container arranged within the carrier.
Preferably, according to another embodiment, the medicament container of the medicament delivery device is a syringe, a cartridge or a collapsible bag.
Preferably, according to another embodiment, the medicament container of the medicament delivery device is made of glass material or plastic material.
Preferably, according to another embodiment, the medicament delivery device is an injection device, an inhalation device, or a medical sprayer.
Preferably, according to another embodiment, the medicament delivery device is an autoinjector.
Preferably, according to another embodiment, the medicament delivery member is an injection needle or a spray nozzle.
The medicament delivery devices described herein can be used for the treatment and/or prophylaxis of one or more of many different types of disorders. Exemplary disorders include, but are not limited to: rheumatoid arthritis, inflammatory bowel diseases (e.g. Crohn’s disease and ulcerative colitis), hypercholesterolaemia, diabetes (e.g. type 2 diabetes), psoriasis, migraines, multiple sclerosis, anaemia, lupus, atopic dermatitis, asthma, nasal polyps, acute hypoglycaemia, obesity, anaphylaxis and allergies. Exemplary types of drugs that could be included in the medicament delivery devices described herein include, but are not limited to, small molecules, hormones, cytokines, blood products, antibodies, antibody-drug conjugates, bispecific antibodies, proteins, fusion proteins, peptibodies, polypeptides, pegylated proteins, protein fragments, protein analogues, protein variants, protein precursors, chimeric antigen receptor T cell therapies, cell or gene therapies, oncolytic viruses, or immunotherapies and/or protein derivatives. Exemplary drugs that could be included in the medicament delivery devices described herein include, but are not limited to (with non-limiting examples of relevant disorders in brackets): etanercept (rheumatoid arthritis, inflammatory bowel diseases (e.g. Crohn’s disease and ulcerative colitis)), evolocumab (hypercholesterolaemia), exenatide (type 2 diabetes), secukinumab (psoriasis), erenumab (migraines), alirocumab (rheumatoid arthritis), methotrexate (amethopterin) (rheumatoid arthritis), tocilizumab (rheumatoid arthritis), interferon beta-1 a (multiple sclerosis), sumatriptan (migraines), adalimumab (rheumatoid arthritis), darbepoetin alfa (anaemia), belimumab (lupus), peginterferon beta-1 a' (multiple sclerosis), sarilumab (rheumatoid arthritis), semaglutide (type 2 diabetes, obesity), dupilumab (atopic dermatitis, asthma, nasal polyps, allergies), glucagon (acute hypoglycaemia), epinephrine (anaphylaxis), insulin (diabetes), atropine and vedolizumab (inflammatory bowel diseases (e.g. Crohn’s disease and ulcerative colitis)) , ipilimumab, nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, cemiplimab, rituximab, trastuzumab, ado-trastuzumab emtansine, fam-trastuzumab deruxtecan-nxki, pertuzumab, transtuzumab-pertuzumab, alemtuzumab, belantamab mafodotin-blmf, bevacizumab, blinatumomab, brentuximab vedotin, cetuximab, daratumumab, elotuzumab, gemtuzumab ozogamicin, 90- Yttrium-
ibritumomab tiuxetan, isatuximab, mogamulizumab, moxetumomab pasudotox, obinutuzumab, ofatumumab, olaratumab, panitumumab, polatuzumab vedotin, ramucirumab, sacituzumab govitecan, tafasitamab, or margetuximab. Pharmaceutical formulations including, but not limited to, any drug described herein are also contemplated for use in the medicament delivery devices described herein, for example pharmaceutical formulations comprising a drug as listed herein (or a pharmaceutically acceptable salt of the drug) and a pharmaceutically acceptable carrier. Pharmaceutical formulations comprising a drug as listed herein (or a pharmaceutically acceptable salt of the drug) may include one or more other active ingredients, or may be the only active ingredient present.
Exemplary drugs that could be included in the medicament delivery devices described herein include, but are not limited to, an immuno-oncology or bio-oncology medications such as immune checkpoints, cytokines, chemokines, clusters of differentiation, interleukins, integrins, growth factors, enzymes, signaling proteins, pro-apoptotic proteins, anti-apoptotic proteins, T-cell receptors, B-cell receptors, or costimulatory proteins.
Exemplary drugs that could be included in the medicament delivery devices described herein include, but are not limited to, those exhibiting a proposed mechanism of action, such as HER-2 receptor modulators, interleukin modulators, interferon modulators, CD38 modulators, CD22 modulators, CCR4 modulators, VEGF modulators, EGFR modulators, CD79b modulators, Trop-2 modulators, CD52 modulators, BCMA modulators, PDGFRA modulators, SLAMF7 modulators, PD-1/PD-L1 inhibitors/modulators, B-lymphocyte antigen CD19 inhibitors, B-lymphocyte antigen CD20 modulators, CD3 modulators, CTLA-4 inhibitors, TIM-3 modulators, VISTA modulators, INDO inhibitors, LAG3 (CD223) antagonists, CD276 antigen modulators, CD47 antagonists, CD30 modulators, CD73 modulators, CD66 modulators, CDw137 agonists, CD158 modulators, CD27 modulators, CD58 modulators, CD80 modulators, CD33 modulators, APRIL receptor modulators, HLA antigen modulators, EGFR modulators, B-lymphocyte cell adhesion molecule modulators, CDw123 modulators, Erbb2 tyrosine kinase receptor modulators, mesothelin modulators, HAVCR2 antagonists, NY-ESO-1 0X40 receptor agonist modulators, adenosine A2 receptors, ICOS modulators, CD40 modulators, TIL therapies, or TCR therapies.
Exemplary drugs that could be included in the medicament delivery devices described herein include, but are not limited to, a multi-medication treatment regimen such as AC, Dose- Dense AC, TCH, GT, EC, TAC, TC, TCHP, CMF, FOLFOX, mFOLFOX6, mFOLFOX7, FOLFCIS, CapeOx, FLOT, DCF, FOLFIRI, FOLFIRINOX, FOLFOXIRI, IROX, CHOP, R- CHOP, RCHOP-21 , Mini-CHOP, Maxi-CHOP, VR-CAP, Dose-Dense CHOP, EPOCH, Dose- Adjusted EPOCH, R-EPOCH, CODOX-M, IVAC, HyperCVAD, R-HyperCVAD, SC-EPOCH- RR, DHAP, ESHAP, GDP, ICE, MINE, CEPP, CDOP, GemOx, CEOP, CEPP, CHOEP, CHP, GCVP, DHAX, CALGB 8811 , HIDAC, MOpAD, 7 + 3, 5 +2, 7 + 4, MEC, CVP,
RBAC500, DHA-Cis, DHA-Ca, DHA-Ox, RCVP, RCEPP, RCEOP, CMV, DDMVAC, GemFLP, ITP, VIDE, VDC, VAI, VDC-IE, MAP, PCV, FCR, FR, PCR, HDMP, OFAR, EMA/CO, EMA/EP, EP/EMA, TP/TE, BEP, TIP, VIP, TPEx, ABVD, BEACOPP, AVD, Mini- BEAM, IGEV, C-MOPP, GCD, GEMOX, CAV, DT-PACE, VTD-PACE, DCEP, ATG, VAC, VelP, OFF, GTX, CAV, AD, MAID, AIM, VAC-IE, ADOC, or PE.
Exemplary drugs that could be included in the medicament delivery devices described herein include, but are not limited to, those used for chemotherapy, such as an alkylating agent, plant alkaloid, antitumor antibiotic, antimetabolite, or topoisomerase inhibitor, enzyme, retinoid, or corticosteroid. Exemplary chemotherapy drugs include, by way of example but not limitation, 5-fluorouracil, cisplatin, carboplatin, oxaliplatin, doxorubicin, daunorubicin, idarubicin, epirubicin, paclitaxel, docetaxel, cyclophosphamide, ifosfamide, azacitidine, decitabine, bendamustine, bleomycin, bortezomib, busulfan, cabazitaxel, carmustine, cladribine, cytarabine, dacarbazine, etoposide, fludarabine, gemcitabine, irinotecan, leucovorin, melphalan, methotrexate, pemetrexed, mitomycin, mitoxantrone, temsirolimus, topotecan, valrubicin, vincristine, vinblastine, or vinorelbine.
Furthermore, all terms used in the claims are to be interpreted according to their ordinary meaning in the technical field, unless explicitly defined otherwise herein. All references to "a/an/the element, apparatus, component, means, etc.” are to be interpreted openly as referring to at least one instance of the element, apparatus, component, means, etc., unless explicitly stated otherwise.
BRIEF DESCRIPTION OF THE DRAWINGS
Embodiments of the inventive concept will now be described, by way of example only, with reference to the accompanying drawings, in which:
Fig. 1 schematically shows a perspective view of a sub-assembly of the invention in an initial state;
Fig. 2 schematically shows a perspective view of the sub-assembly of Fig. 1 in a ready-to- be-used state;
Fig. 3 schematically shows a perspective view of another example of the sub-assembly of the invention in an initial state;
Fig. 4 schematically shows a perspective view of the sub-assembly of Fig. 3 in an initial state;
Fig. 5 schematically shows a perspective view of components of the sub-assembly of Fig. 1 .
Fig. 6 schematically shows a perspective view of components of the sub-assembly of Fig. 3.
Figs 7A-E schematically show perspective views of an operation sequence of the subassembly of Fig. 1 ;
Figs 8A-B schematically show perspective views of an operation sequence of the subassembly of Fig. 3;
Fig. 9 schematically shows a perspective view of a delivery member guard of the subassembly of the invention and a cap assembly of the sub-assembly of the invention;
Figs 10-11 schematically show perspective views of the cap assembly of Fig. 9;
Fig. 12 schematically shows a perspective view of a cap of the cap assembly of Fig. 9;
Fig. 13 schematically shows a perspective view of a clutch member of the sub-assembly of the invention;
Figs 14-15 schematically show a perspective view of the cap assembly of Fig. 9 with the clutch member of Fig. 13.
DETAILED DESCRIPTION
Figs 1-15 illustrate many examples of a sub-assembly of a medicament delivery device. The sub-assembly comprises a tubular housing 1 ; 1 a delivery member guard 2; 2’, a biasing member, a cap 31 , a connector 5; 5’ and an adapter 6; 6’.
As shown in Figs 1-4, the tubular housing 1 ; 1 ’ extends along a longitudinal axis L between a proximal end and a distal end. The tubular housing 1 ; 1 ' is configured to receive a medicament container of the medicament delivery device. Preferably, the tubular housing 1 ; 1 ' comprises an observation window so that a user of the medicament delivery device can check the condition of the medicament within the medicament container before use. The window can be a transparent portion or an aperture in a wall of the tubular housing 1 ; 1'. Alternatively, the housing can be made of transparent material so that the window is no longer necessary for the user to observe the medicament. In a preferred example, as shown in Figs 2-3, the tubular housing 1 ; 1 ' has a rectangular cross-section perpendicular to the longitudinal axis L, so that the medicament delivery device can be prevented from rolling on a flat surface. It should be noted that such functionality can be obtained by forming the tubular housing 1 ; 1 ' in any shape that has a non-circular cross-section perpendicular to the longitudinal axis L. The tubular housing can be formed by multiple components, or the tubular housing can be formed by a single component, dependent on the design.
The delivery member guard 2; 2’ comprises a proximal portion 20; 20’ arranged coaxially with the tubular housing 1 ; 1 ’. The proximal portion 20; 20’ is configured to surround a medicament delivery member of the medicament delivery device. The proximal portion 20; 20’ can be tubular, or it can be formed by multiple proximally extending arms. In a preferred example, the delivery member guard 2; 2’ is partially arranged within the housing. In this example, the tubular proximal portion 20; 20’ of the delivery member guard 2; 2’ is arranged telescopically relative to the proximal end of the housing 1 ; 1 ’, as shown in Figs 1-4. Alternatively, the delivery member guard at least partially surrounds a proximal portion of the tubular housing.
The biasing member is operably attached to the tubular housing 1 ; 1 ’ at one end and to the delivery member guard 2; 2’ at the other end. The biasing member is configured to bias the delivery member guard 2; 2’ relative to the housing from a distal position to a proximal position. The biasing member can be a spring, e.g., a compression spring, a tension spring, a band spring; or a flexible arm. In one example where the biasing member is a spring, the tubular housing 1 comprises a proximally directed surface and the delivery member guard comprises a distally directed surface. In this example, the biasing member extends between a first end that is engaged with the proximally directed surface of the housing, and a second end that is engaged with the distally directed surface of the delivery member guard.
The cap 31 is removably attached to the proximal end of the housing 1 ; 1 '. The cap 31 comprises a distally directed surface 311 . The cap 31 is configured to seal a medicament delivery member, e.g., an injection needle or a spray nozzle, of the medicament delivery device. In a preferred example, the cap 31 is configured to be removed from the housing via a rotation of the cap 31 around the longitudinal axis L of the tubular housing 1 and relative to the tubular housing. In this example, the cap 31 is engaged with the tubular housing 1 via a threaded engagement or a bayonet engagement. Alternatively, the cap is configured to be removed from the tubular housing via a linear movement relative to the housing. For example, the cap is configured to be pulled by a user of the medicament delivery device.
The connector 5; 5’ comprises a proximally directed surface 501 ; 501 ’ operably engaged with the distally directed surface 311 of the cap 31 and comprises a distally directed surface 51 a; 51 a’. Therefore, the connector 5; 5’ is axially immovable relative to the cap 31 in the proximal direction of the tubular housing 1 ; 1 ’.
In a preferred example, the connector 5; 5’ comprises a body. The connector 5’ comprises a ledge 51 ’ extending from an inner surface of the body of the connector 5’ towards the longitudinal axis L, as shown in Fig. 6. The ledge 51 ’ comprises the distally directed surface 51 a’ of the connector 5’. Alternatively, the ledge 51 extends from an outer surface of the
body of the connector 5 away from the longitudinal axis, as shown in Fig. 5. The ledge 51 comprises the distally directed surface 51 a of the connector 5.
In one example, the body of the connector 5; 5’ is generally cylindrical. In a preferred example, the body of the connector 5’ is a ring-shaped body.
The adapter 6; 6’ is operably connected to the delivery member guard 2; 2’ such that the adapter s; 6’ is axially immovable relative to the delivery member guard 2; 2’ when the delivery member guard 2; 2 is in the distal position. In one example, the adapter 6; 6’ comprises a distally directed surface engaged with a proximally directed surface of the delivery member guard 2; 2’ directly, as shown in Figs 7A-7D and Fig. 8A. Alternatively, the adapter is an integral part of the proximal portion of the delivery member guard. The adapter 6; 6’ comprises a proximally directed surface 60a; 60a’ engaged with the distally directed surface 51 a; 51 a’ of the connector 5; 5’ when the connector 5; 5’ is in a first position.
Therefore, the delivery member guard 2; 2’ is blocked from moving in the proximal direction relative to the tubular housing 1 . The proximally directed surface 60a; 60a’ of the adapter 6; 6’ is disengaged from the distally directed surface 51 a; 51 a’ of the connector 5; 5’ when the connector 5; 5’ is in a second position such that the proximal portion 20; 20’ of the delivery member guard 2; 2’ can be biased to the proximal position by the biasing member. In one example where the adapter is an integral part of the proximal portion of the delivery member guard, the adapter comprises a ledge extending from a wall of the proximal portion of the delivery member guard. The ledge comprises the proximally directed surface of the adapter.
Alternatively, the adapter 6; 6’ is an independent component separate from the delivery member guard, as shown in Figs 5-6. In a preferred example, the adapter 6; 6’ comprises a ring-shaped body, as shown in Figs 5-6.
It should be noted that the term ‘ring-shaped body’ used in this description means that the body comprises a wall enclosing the longitudinal axis L.
In this example, the ring-shaped body comprises the distally directed surface engaged with the proximally directed surface of the delivery member guard when the delivery member guard is in the distal position. In a preferred example, the distally directed surface of the adapter 6; 6’ is defined by the distal end edge of the ring-shaped body, and the proximal directed surface of the delivery member guard 2; 2’ is defined by the proximal end edge of the proximal portion 20; 20’.
The connector 5; 5' is configured to be rotated relative to the adapter 6; 6 around the longitudinal axis L between the first position and the second position. In one example, the connector 5 is configured to be rotated relative to the tubular housing 1 around the longitudinal axis L between the first position and the second position. Alternatively, the
adapter 6' is configured to rotate relative to the tubular housing 1 around the longitudinal axis L between the first position of the connector s' and the second position of the connector 5'.
In one example, the adapter s; 6’ comprises a ledge 60; 60 extending from an inner surface of the ring-shaped body. The ledge comprises the proximally directed surface 60a; 60a’ of the adapter 6; 6’. As shown in Figs 7A and 8A, the proximally directed surface 60a; 60a’ of the adapter s; 6’ is engaged with the distally directed surface 51 a; 51 a’ of the connector 5; 5’ when the connector 5; 5’ is in the first position. When the connector 5; 5’ is rotated around the longitudinal axis L relative to the adapter 6; 6’ into the second position (as shown with the arrow R1), the proximally directed surface 60a; 60a’ of the adapter 6; 6’ is disengaged from the distally directed surface 51 a; 51 a’ of the connector 5; 5’, as shown in Fig 7D and Fig. 8B.
In one example, the proximally directed surface 501 of the connector 5 is directly engaged with the distally directed surface 311 of the cap 31 , as shown in Fig. 8A. Alternatively, the proximally directed surface 501 ' of the connector 5' is indirectly engaged with a tubular outer cap 30 which is engaged with the distally directed surface 311 of the cap 31 , as shown in Fig. 7A. With the mentioned engagement between the cap 31 and the connector 5; 5’, when the connector 5; 5’ is in the first position, the delivery member guard 2; 2’ is prevented from moving in the proximal direction relative to the tubular housing 1 .
In one example, the connector 5 is accessible to the user of the medicament delivery device, as shown in Figs 1-2. In this example, the connector 5 is the tubular outer cap 30 of the medicament delivery device. In this example, the connector 5 is configured to be manually rotated by the user from the first position to the second position when the user plans to use the medicament delivery device.
As shown in Fig. 2, when the user rotates the connector 5 to the second position, as the proximally directed surface 60a of the adapter 6 is disengaged from the distally directed surface 51 a of the connector 5 (as shown in Fig. 8B), the delivery member guard 2 is biased to its proximal position by the biasing member. Therefore, an indication can be provided to the user that the device is ready to be used. In a preferred example, the proximal portion of the delivery member guard comprises a color different to the tubular housing and the cap, and/or a mark for indication purposes. For example, the tubular housing may be white, and the cap may be red, in this example, the proximal portion of the delivery member guard can be yellow or green.
Optionally, in this example, the adapter 6 comprises an engaging member 61 and the housing comprises a counter engaging member 11 engaged with the engaging member 61 , as shown in Figs 1-2, such that the adapter 6 is rotationally immovable relative to the housing 1 when the delivery member guard 2 is in the distal position. Therefore, the user can
only disengage the proximally directed surface 60a of the adapter 6 from the distally directed surface 51 a of the connector 5 by rotating the connector 5. In one example where the connector 5 is the tubular outer cap 30 of the medicament delivery device, the rotation of the connector from the first position to the second position is a part of the action causing the cap to be removed from the tubular housing 1 .
In a preferred example, the engaging member 61 of the adapter 6 and the counter engaging member 11 of the tubular housing 1 form at least one of a rib-and-rib engagement, a rib-and- recess engagement, and a rib-and-cut-out engagement.
In another example, instead of the connector, the adapter is configured to be manually rotated by the user relative to the connector around the longitudinal axis L of the tubular housing. Preferably, in this example, the connector 5' is covered by the tubular outer cap 30 of the medicament delivery device, as shown in Fig. 3 and Fig. 7 A, such that the user cannot access to the connector 5’ and therefore, the connector 5’ cannot be manually rotated by the user. In this example, the adapter 6’ comprises an engaging member 61 ’ and the cap 31 comprises a counter engaging member 312 engaged with the engaging member 61 ’ (as shown in Fig. 7B) such that the adapter 6’ is rotationally immovable relative to the cap 31 when the delivery member guard 2’ is in the distal position. Therefore, when the user rotates the cap 31 , the user rotates the adapter 6’ relative to the connector 5’ from the first position of the connector 5’ to the second position of the connector 5’. In one example, the engaging member 61 ’ of the adapter and the counter engaging member of the cap forme a rib-and-rib engagement, a rib-and-recess engagement, or a rib-and-cut-out engagement. Alternatively, the engaging member 61 ’ of the adapter 6’ comprises a non-circular cross-section perpendicular to the longitudinal axis L, and the counter engaging member 312 of the cap 31 comprises a counter non-circular cross-section perpendicular to the longitudinal axis L, as shown in Fig. 7B. In one example where the adapter 6’ comprises the ring-shaped body, the engaging member 61 ’ of the adapter 6’ is the inner circumferential surface 61 ’ of the ringshaped body of the adapter 6’.
Figs 7A-7E will also be used to explain another example where the connector 5’ is configured to be manually rotated by the user via the outer cap 30. This example will be explained later.
Furthermore, in one example, the sub-assembly comprises a delivery member cover assembly 3. The delivery member cover assembly 3 comprises the tubular outer cap 30 and a clutch member 32. The cap 31 is at least partially surrounded by the tubular outer cap 30. The clutch member 32 is rotationally fixed to the cap 31 and positioned longitudinally between the tubular outer cap 30 and the delivery member guard 2; 2’. The clutch member 32 comprises a clutch biasing member 320. The clutch member 32 is axially movable
relative to the outer cap 30 from a relaxed position to a tensioned position when the delivery member guard 2; 2’ is moved from the distal position to the proximal position. The tubular outer cap 30 is axially fixed with and rotatable relative to the cap 31 . The tubular outer cap 30 comprises an engaging member 301 and the clutch member 32 comprises a counter engaging member 33. The engaging member 301 is adjacent to the counter engaging member 33 when the clutch biasing member 320 is in the related position.
In one example where the connector 5 is the tubular outer cap 30, the connector 5 is rotatable relative to the cap 31 when the clutch biasing member is in the tensioned position. As mentioned above, the connector 5 is axially immovable relative to the cap 31 by the distally directed surface 311 of the cap 31 and the proximally directed surface 501 of the connector 5. As there is no rotationally limiting structure between the connector 5 and the cap 31 , the connect 5 can freely rotate relative to the cap 31 . In one example, the connector 5 comprises a hook 302 positioned within an annular groove of the cap 31 . The hook 302 comprises the proximally directed surface 501 of the connector 5. The edge of the annular groove of the cap 31 comprises the distally directed surface 311 , as shown in Fig. 8A. When the user turns the tubular outer cap 30, meaning that the user is turning the connector 5 from the first position to the second position relative to the adapter 6, the delivery member guard 2 is released and is biased to the proximal position by the biasing member. When the delivery member guard 2 is in the proximal position, the clutch biasing member 320 is compressed from its relaxed position to the tensioned position. Therefore, the engaging member 301 of the tubular outer cap 30 is adjacent to the counter engaging member 33 of the clutch member 32. Thus, when the user further turns the tubular outer cap 30 relative to the tubular housing 1 around the longitudinal axis, the engaging member 301 and the counter engaging member 33 are engaged, and thus, the clutch member 32 and the tubular outer cap 30 are both rotated. As the clutch member 32 is rotationally fixed to the cap 31 , the rotation of the clutch member 32 causes the cap 31 to be rotated, and therefore, the cap 31 can be detached from the tubular housing 1 .
The engagement between cap 31 and the clutch member 32 can be a rib-and-rib engagement, a rib-and-recess engagement, or a rib-and-cut-out engagement. Alternatively, an engaging member 322a of the clutch member comprises a non-circular cross-section perpendicular to the longitudinal axis L. The counter engaging member 312 of the cap 31 is a counter non-circular cross-section perpendicular to the longitudinal axis L, as shown in Figs 12-13.
In one example, the engaging member 301 of the tubular outer cap 30 is a protrusion extending from an inner wall of the tubular outer cap 30 towards the longitudinal axis L. In a
preferred example, as shown in Fig. 10, the engaging member 301 is a rack. In a preferred example, the engaging member 301 is a set of ratchet teeth.
In one example, the counter engaging member 33 of the clutch member 32 is a counter protrusion 33 extending radially outwardly relative to the longitudinal axis L from an outer surface of the cap 31 . In a preferred example, the counter engaging member 33 comprises a flexible arm 331 extending partially around the longitudinal axis L, as shown in Fig. 13. In this example, the user can get an audible and/or a tactile indication if the user turns the tubular outer cap 30 in the direction that cannot result in removal of the cap 31 .
Furthermore, in one example, the clutch member 32 comprises a proximal portion 321 and a distal portion 322. The clutch biasing member 320 is longitudinally positioned between the proximal portion 321 and the distal portion 322, as shown in Fig. 9. The proximal portion 321 is releasably engaged with a distally directed surface on the inner surface of the tubular outer cap 30. In this example, the counter engaging member 33 of the clutch member 32 is arranged on an outer surface of the distal portion 322.
In one example, the adapter 6’ is the distal portion 322 of the clutch member 32, as shown in Fig. 7A and Fig. 7D. In one example where the connector 5’ is an independent component from the tubular outer cap 30, the connector 5’ is positioned longitudinally between the tubular outer cap 30 and the delivery member guard 2’ and is positioned at least partially between the tubular outer cap 30 and the clutch member 32, as shown in Fig. 7A. In this example, the connector 5’ is rotatable relative to the clutch member 32. The connector 5’ comprises a rotational engaging member 52’ configured to engage with a counter rotational engaging member 301 of the tubular outer cap 30. Therefore, the connector 5’ is manually rotated from the first position to the second position via a rotation of the tubular outer cap 30 relative to the cap 31 .
In one example, the counter rotational engaging member 301 of the tubular outer cap 30 is the engaging member 301 of the tubular outer cap 30. In this example, when the clutch biasing member 320 is in the tensioned position, the counter engaging member 33 of the clutch member 32 is spaced apart from the engaging member 301 of the tubular outer cap 30, and the rotational engaging member 52’ of the connector 5’ is adjacent to the engaging member 301 of the tubular outer cap 30. Therefore, when the user rotates the tubular outer cap 30 relative to the tubular housing 1 around the longitudinal axis L, the connector 5’ is also rotated from its first position to the second position (as shown in Fig. 7D with the arrow R1). When the connector 5’ is in the second position, the adapter 6’, namely, the distal portion 322 of the clutch member 32 in this example, is moved in the proximal position relative to the tubular outer cap 30 by the biased delivery member guard 2’. Therefore, when
the delivery member guard is in the proximal position, the counter engaging member 33 of the clutch member 32 is adjacent to the engaging member 301 of the tubular outer cap 30, as mentioned above. The user can remove the cap 31 by further rotating the tubular outer cap 30 (as shown in Fig. 7E with the arrow R2).
In one preferred example, the rotational engaging member 52’ of the connector 5’ is a protrusion. In a preferred example, the rotational engaging member 52’ and the counter rotational engaging member 301 form a ratchet engagement such that the connector is only rotationally fixed to the tubular outer cap in one rotational direction. Similar to the clutch member 32 mentioned above, the rotational engaging member 52’ of the connector 5' may comprise a flexible arm extending in the radial direction such that an audible and/or tactile indication is generated when the user rotates the tubular outer cap 30 in the direction that will not result in the removal of the cap 31 .
It should be noted that the clutch member 32 is configured to control the cap removal in a specific order, namely, the cap 31 should not be removed before the delivery member guard moves to the proximal position. This example is useful if the proximal movement of the delivery member guard and the cap removal are all linked to at least one specific function. For example, the proximal movement of the delivery member guard may be configured to trigger a mixing operation between multiple chambers of the medicament container, and the cap removal may be configured to cause a medicament delivery member to be mounted to the medicament container. In this example, if the medicament delivery member is mounted to the medicament container, the mixing operation may not work properly, as the increased pressure within the medicament container will cause the medicament to be expelled rather than enter into another chamber. However, if the cap removal and the proximal movement of the delivery member guard do not need to be carried out in a specific order, for example, the proximal movement of the delivery member guard is configured to be a tamper-evident that indicates the user that the sterilization of the medicament delivery member is changed (as the cap has been turned). In this example, there is not necessary to have the clutch member. The connector can be moved from the first position to the second position relative to the adapter during the cap removal.
Furthermore, the housing of the medicament delivery device, as mentioned in any example, may be provided with (i.e., molded in, molded with) a compound featuring persistently antimicrobial, antifungal, and/or antiviral properties. Alternatively, a compound featuring persistently antimicrobial, antifungal, and/or antiviral properties may be applied to the molded (i.e., finished) components through secondary processes (e.g., chemical vapor deposition), spraying, or dipping processes.
The inventive concept has mainly been described above with reference to a few examples. However, as is readily appreciated by a person skilled in the art, other embodiments than the ones disclosed above are equally possible within the scope of the inventive concept, as defined by the appended claims.
Some aspects of the invention are defined by the following clauses.
1 . A sub-assembly of a medicament delivery device, the sub-assembly comprising: a tubular housing (1 ; 1 ’) extending along a longitudinal axis (L) between a proximal end and a distal end; a delivery member guard (2; 2’) comprising a proximal portion (20; 20’) arranged coaxially with the tubular housing (1); wherein the proximal portion (20; 20’) is configured to surround a medicament delivery member of the medicament delivery device; a biasing member operably attached to the housing (1 ; 1 ’) at one end and to the delivery member guard (2; 2’) at the other end; wherein the biasing member is configured to bias the delivery member guard (2; 2’) relative to the housing from a distal position to a proximal position; a cap (31) removably attached to the proximal end of the housing (1 ; 1 ’); wherein the cap (31) comprises a distally directed surface (311); a connector (5; 5’) comprising a proximally directed surface (501 ; 501 ’) operably engaged with the distally directed surface (311) of the cap (31) and comprising a distally directed surface (51 a; 51 a’); an adapter (6; 6’) operably connected to the delivery member guard (2; 2’) such that the adapter (6; 6’) is axially immovable relative to the delivery member guard (2; 2’) when the delivery member guard (2; 2) is in the distal position; wherein the adapter (6; 6’) comprises a proximally directed surface (60a; 60a’); and wherein the connector (5; 5’) is rotatable around the longitudinal axis (L) relative to the adapter (6; 6’) between a first position where the distally directed surface (51 a; 51 a’) of the connector (5; 5’) is engaged with the proximally directed surface (60a; 60a’) of the adapter (6; 6’) such that the proximal portion (20; 20’) of the delivery member guard (2; 2’) is blocked from being biased to the proximal position and a second position where the distally directed surface (51 a; 51 a’) of the connector (5; 5’) is offset relative to the proximally directed surface (60a; 60a’) of the adapter (6; 6’) such that the proximal portion (20; 20’) of the delivery member guard (2; 2’) can be biased to the proximal position by the biasing member.
2. The sub-assembly according to clause 1 , wherein the adapter comprises a ledge extending from a wall of the proximal portion of the delivery member guard; and wherein the ledge comprises the proximally directed surface of the adapter.
3. The sub-assembly according to clause 1 , wherein the adapter comprises a ringshaped body; wherein the adapter comprises a ledge extending from an inner surface of the ring-shaped body; wherein the ring-shaped body comprises a distally directed surface; and wherein the proximal portion of the delivery member guard comprises a proximally directed surface engaged with the distally directed surface of the ring-shaped body.
4. The sub-assembly according to clause 3, wherein the adapter comprises an engaging member (61) and the housing comprises a counter engaging member (11) engaged with the engaging member such that the adapter is rotationally immovable relative to the housing when the delivery member guard is in the distal position.
5. The sub-assembly according to clause 4, wherein the engaging member and the counter engaging member form at least one of a rib-and-rib engagement, a rib-and- recess engagement, and a rib-and-cut-out engagement.
6. The sub-assembly according to clause 3, wherein the adapter comprises an engaging member and the cap comprises a counter engaging member engaged with the engaging member such that the adapter is rotationally immovable relative to the cap when the delivery member guard is in the distal position.
7. The sub-assembly according to clause 6, wherein the engaging member comprises a non-circular cross-section perpendicular to the longitudinal axis, and the counter engaging member comprises a counter non-circular cross-section perpendicular to the longitudinal axis.
8. The sub-assembly according to clause 7, wherein the engaging member of the adapter is an inner circumferential surface of the ring-shaped body of the adapter.
9. The sub-assembly according to any of the preceding clauses, wherein the connector comprises a body; wherein the connector comprises a ledge extending from an inner surface of the body of the connector towards the longitudinal axis; and wherein the ledge comprises the distally directed surface of the connector.
10. The sub-assembly according clause 9 when dependent on clause 3, wherein the body of the connector is the ring-shaped body.
11 . The sub-assembly according to any of the preceding clauses, comprising a delivery member cover assembly; wherein the delivery member cover assembly comprises: a tubular outer cap and a clutch member; wherein the cap is at least partially surrounded by the tubular outer cap; wherein the clutch member is rotationally fixed to the cap and positioned longitudinally between the tubular outer cap and the delivery member guard; wherein the clutch member comprises a clutch biasing member, the clutch member being axially movable relative to the outer cap from a relaxed position to a tensioned position when the delivery member guard is moved from the distal position to the proximal position; wherein the tubular outer cap is axially fixed with and rotatable relative to the cap; wherein the tubular outer cap comprises an engaging member and the clutch member comprises a counter engaging member; and wherein the plurality of engaging members is adjacent to the plurality of counter engaging members when the clutch biasing member is in the tensioned position.
12. The sub-assembly according to clause 11 , wherein the connector is the tubular outer cap.
13. The sub-assembly according to clause 11 , wherein the connector is positioned longitudinally between the tubular outer cap and the delivery member guard and is positioned at least partially between the tubular outer cap and the clutch member; wherein the connector is rotatable relative to the clutch member; wherein the connector comprises a rotational engaging member; wherein the outer cap comprises a counter rotational engaging member engaged with the rotational engaging member such that the connector is manually rotated from the first position to the second position via a rotation of the tubular outer cap relative to the cap.
14. The sub-assembly according to clauses 11-13, wherein the engaging member of the tubular outer cap is the counter rotational engaging member.
15. The sub-assembly according to clauses 14, wherein the rotational engaging member of the connector is a counter protrusion; and wherein the rotational engaging member and the counter rotational engaging member form a ratchet engagement such that the connector is only rotationally fixed to the tubular outer cap in one rotational direction.
16. The sub-assembly according to any of clauses 11-15, wherein the clutch member comprises a proximal portion and a distal portion; wherein the clutch biasing member is longitudinally positioned between the proximal portion and the distal portion; wherein the proximal portion is releasably engaged with a distally directed surface on the inner surface of the tubular outer cap; and wherein the adapter is the distal portion of the clutch member.
17. The sub-assembly according to any of clauses 11-16, wherein the counter engaging member of the clutch member is a plurality of counter protrusions; wherein the counter protrusion extends radially outwardly relative to the longitudinal axis from an outer surface of the cap.
18. The sub-assembly according to clause 17, wherein the counter engaging member of the clutch member is arranged on an outer surface of the distal portion.
19. The sub-assembly according to clause 11-18, wherein the plurality of counter engaging members comprises a flexible arm extending partially around the longitudinal axis.
20. The sub-assembly according to any of the preceding clauses, wherein the delivery member guard is partially arranged within the housing; wherein the tubular proximal portion of the delivery member guard is arranged telescopically relative to the proximal end of the housing.
21. The sub-assembly according to any of the preceding clauses, wherein the housing comprises a proximally directed surface; wherein the delivery member guard comprises a distally directed surface; and wherein the biasing member is a spring extending between a first end engaged with the proximally directed surface of the housing and a second end engaged with the distally directed surface of the delivery member guard.
Claims
1 . A sub-assembly of a medicament delivery device, the sub-assembly comprising: a tubular housing (1 ; 1 ’) extending along a longitudinal axis (L) between a proximal end and a distal end; a delivery member guard (2; 2’) comprising a proximal portion (20; 20’) arranged coaxially with the tubular housing (1); wherein the proximal portion (20; 20’) is configured to surround a medicament delivery member of the medicament delivery device; a biasing member operably attached to the housing (1 ; 1 ’) at one end and to the delivery member guard (2; 2’) at the other end; wherein the biasing member is configured to bias the delivery member guard (2; 2’) relative to the housing from a distal position to a proximal position; a cap (31) removably attached to the proximal end of the housing (1 ; 1 ’); wherein the cap (31) comprises a distally directed surface (311); a connector (5; 5’) comprising a proximally directed surface (501 ; 501 ’) operably engaged with the distally directed surface (311) of the cap (31) and comprising a distally directed surface (51 a; 51 a’); an adapter (6; 6’) operably connected to the delivery member guard (2; 2’) such that the adapter (6; 6’) is axially immovable relative to the delivery member guard (2; 2’) when the delivery member guard (2; 2) is in the distal position; wherein the adapter (6; 6’) comprises a proximally directed surface (60a; 60a’); and wherein the connector (5; 5’) is rotatable around the longitudinal axis (L) relative to the adapter (6; 6’) between a first position where the distally directed surface (51 a; 51 a’) of the connector (5; 5’) is engaged with the proximally directed surface (60a; 60a’) of the adapter (6; 6’) such that the proximal portion (20; 20’) of the delivery member guard (2; 2’) is blocked from being biased to the proximal position and a second position where the distally directed surface (51a; 51 a’) of the connector (5; 5’) is offset relative to the proximally directed surface (60a; 60a’) of the adapter (6;
6’) such that the proximal portion (20; 20’) of the delivery member guard (2; 2’) can be biased to the proximal position by the biasing member.
2. The sub-assembly according to claim 1 , wherein the adapter comprises a ledge extending from a wall of the proximal portion of the delivery member guard; and wherein the ledge comprises the proximally directed surface of the adapter.
3. The sub-assembly according to claim 1 , wherein the adapter comprises a ringshaped body; wherein the adapter comprises a ledge extending from an inner surface of the ring-shaped body; wherein the ring-shaped body comprises a distally
directed surface; and wherein the proximal portion of the delivery member guard comprises a proximally directed surface engaged with the distally directed surface of the ring-shaped body.
4. The sub-assembly according to claim 3, wherein the adapter comprises an engaging member (61) and the housing comprises a counter engaging member (11) engaged with the engaging member such that the adapter is rotationally immovable relative to the housing when the delivery member guard is in the distal position.
5. The sub-assembly according to claim 4, wherein the engaging member and the counter engaging member form at least one of a rib-and- rib engagement, a rib-and- recess engagement, and a rib-and-cut-out engagement.
6. The sub-assembly according to claim 3, wherein the adapter comprises an engaging member and the cap comprises a counter engaging member engaged with the engaging member such that the adapter is rotationally immovable relative to the cap when the delivery member guard is in the distal position.
7. The sub-assembly according to claim 6, wherein the engaging member comprises a non-circular cross-section perpendicular to the longitudinal axis, and the counter engaging member comprises a counter non-circular cross-section perpendicular to the longitudinal axis.
8. The sub-assembly according to claim 7, wherein the engaging member of the adapter is an inner circumferential surface of the ring-shaped body of the adapter.
9. The sub-assembly according to any of the preceding claims, wherein the connector comprises a body; wherein the connector comprises a ledge extending from an inner surface of the body of the connector towards the longitudinal axis; and wherein the ledge comprises the distally directed surface of the connector.
10. The sub-assembly according claim 9 when dependent on claim 3, wherein the body of the connector is the ring-shaped body.
11 . The sub-assembly according to any of the preceding claims, comprising a delivery member cover assembly; wherein the delivery member cover assembly comprises: a tubular outer cap and a clutch member; wherein the cap is at least partially surrounded by the tubular outer cap; wherein the clutch member is rotationally fixed to the cap and positioned longitudinally between the tubular outer cap and the delivery member guard;
wherein the clutch member comprises a clutch biasing member, the clutch member being axially movable relative to the outer cap from a relaxed position to a tensioned position when the delivery member guard is moved from the distal position to the proximal position; wherein the tubular outer cap is axially fixed with and rotatable relative to the cap; wherein the tubular outer cap comprises an engaging member and the clutch member comprises a counter engaging member; and wherein the plurality of engaging members is adjacent to the plurality of counter engaging members when the clutch biasing member is in the tensioned position. The sub-assembly according to claim 11 , wherein the connector is the tubular outer cap. The sub-assembly according to claims 11 or 12, wherein the engaging member of the tubular outer cap is the counter rotational engaging member. The sub-assembly according to any of the preceding claims, wherein the delivery member guard is partially arranged within the housing; wherein the tubular proximal portion of the delivery member guard is arranged telescopically relative to the proximal end of the housing. The sub-assembly according to any of the preceding claims, wherein the housing comprises a proximally directed surface; wherein the delivery member guard comprises a distally directed surface; and wherein the biasing member is a spring extending between a first end engaged with the proximally directed surface of the housing and a second end engaged with the distally directed surface of the delivery member guard.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22205559.2 | 2022-11-04 | ||
EP22205559 | 2022-11-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024094439A1 true WO2024094439A1 (en) | 2024-05-10 |
Family
ID=84245773
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/079217 WO2024094439A1 (en) | 2022-11-04 | 2023-10-20 | A sub-assembly of a medicament delivery device |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024094439A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021115718A1 (en) * | 2019-12-11 | 2021-06-17 | Shl Medical Ag | A medicament delivery device |
WO2021190779A1 (en) * | 2020-03-26 | 2021-09-30 | Shl Medical Ag | Locking mechanism for a medicament delivery device |
WO2022228936A1 (en) * | 2021-04-28 | 2022-11-03 | Shl Medical Ag | A cassette unit sub-assembly for a medicament delivery device |
-
2023
- 2023-10-20 WO PCT/EP2023/079217 patent/WO2024094439A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021115718A1 (en) * | 2019-12-11 | 2021-06-17 | Shl Medical Ag | A medicament delivery device |
WO2021190779A1 (en) * | 2020-03-26 | 2021-09-30 | Shl Medical Ag | Locking mechanism for a medicament delivery device |
WO2022228936A1 (en) * | 2021-04-28 | 2022-11-03 | Shl Medical Ag | A cassette unit sub-assembly for a medicament delivery device |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10010482B2 (en) | Syringe fill system and method | |
US20210228818A1 (en) | Pre-Filled Disposable Injection Device | |
US11904151B2 (en) | Cap for an injection device | |
US20060104971A1 (en) | Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof | |
CN109069749B (en) | Drug delivery device | |
RU2004105951A (en) | INTRODUCTION DEVICE CONTAINING A DOSING DEVICE | |
TW201125598A (en) | Metered liquid droplet inhaler | |
EP3370804B1 (en) | Cartridge carrier assembly | |
WO2024094439A1 (en) | A sub-assembly of a medicament delivery device | |
CN104768596B (en) | The delivery device of pin actuator with shielding part operation | |
WO2024094441A1 (en) | A sub-assembly of a medicament delivery device | |
WO2024126094A1 (en) | A sub-assembly of a medicament delivery device | |
WO2024094440A1 (en) | A reusable drive unit of a medicament delivery device | |
WO2024083511A1 (en) | A sub-assembly of a medicament delivery device | |
WO2023131550A1 (en) | A sub-assembly of a medicament delivery device | |
WO2024126093A1 (en) | Safety injection device for delivering a drug | |
WO2024052239A1 (en) | Dosing apparatus for parenteral delivery of fluids | |
WO2024110209A1 (en) | A distal lid of a medicament delivery device | |
WO2024121118A1 (en) | A sub-assembly for a medicament delivery device | |
WO2024121117A1 (en) | A lock component for a medicament delivery device | |
WO2023237357A1 (en) | Drug delivery control arrangement, and injector | |
CN113164689B (en) | Auxiliary device for an injection device | |
WO2024042040A1 (en) | Injection assembly | |
WO2024008451A1 (en) | A sub-assembly of a pump device | |
JP2023520053A (en) | Injection device storage container |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23793362 Country of ref document: EP Kind code of ref document: A1 |